A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guerin in Patients with High-risk Non- muscle-invasive Bladder Cancer

Meeting Abstract Oncology

Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.

Sam S. Chang et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

T. Powles et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Marko Babjuk et al.

Summary: The updated EAU guidelines provide new information on the diagnosis and treatment of NMIBC for clinical practice. Individual risk assessment is crucial in determining the appropriate treatment for patients with different risk levels. Surgical intervention, including radical cystectomy, may be necessary for cases unresponsive to BCG treatment or with high risk of progression.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

J. Alfred Witjes et al.

Summary: This article presents the updated European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, providing practical evidence-based recommendations and consensus statements on clinical management. The guidelines cover a broad scope and incorporate the latest research findings and results from consensus meetings.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian et al.

Summary: The study demonstrates the efficacy of intravesical nadofaragene firadenovec, a novel therapy using a replication-deficient recombinant adenovirus, in patients with BCG-unresponsive non-muscle-invasive bladder cancer, with a favorable benefit:risk ratio. The treatment led to a complete response in a significant proportion of patients with carcinoma in situ, and the adverse events were generally mild, with no treatment-related deaths reported.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt et al.

Summary: IMvigor010 is the largest adjuvant study evaluating a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not show improved disease-free survival with atezolizumab compared to observation. Atezolizumab was generally well tolerated, but higher rates of adverse events leading to discontinuation were reported compared to previous studies on metastatic urothelial carcinoma.

LANCET ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Peter C. Black et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Balar et al.

Summary: This study evaluated the efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The results showed that pembrolizumab monotherapy was well-tolerated and demonstrated promising antitumor activity in this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Urology & Nephrology

Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer

Hyung Suk Kim et al.

Summary: Intravesical BCG immunotherapy is the gold standard adjuvant treatment for non-muscle-invasive bladder cancer, but there is a critical need for alternative bladder-sparing strategies in patients with BCG-unresponsiveness. Ongoing trials and testing of novel agents are aimed at addressing this unmet need.

INVESTIGATIVE AND CLINICAL UROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology